Model-based assessment of pharmacokinetic changes of sunitinib, tacrolimus, and everolimus in a patient with metastatic renal cell carcinoma after renal transplantation-Reference-Cited by-同舟云学术

Model-based assessment of pharmacokinetic changes of sunitinib, tacrolimus, and everolimus in a patient with metastatic renal cell carcinoma after renal transplantation

Published:2020-10 Issue:5 Volume:35 Page:405-409
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Ito Takahiro,Yamamoto Kazuhiro^ORCID,Ogawa Satoshi,Furukawa Junya,Harada Kenichi,Fujisawa Masato,Omura Tomohiro,Yano Ikuko

Funder

JSPS KAKENHI

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference22 articles.

1. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Drug interactions with sunitinib;Bilbao-Meseguer;J Oncol Pharm Pract,2015

4. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Canc Res,2003

5. Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma;Noda;Clin Genitourin Canc,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2‐week‐on and 1‐week‐off schedule;Journal of Clinical Pharmacy and Therapeutics;2021-10-20

2. Azelnidipine/everolimus/sunitinib/tacrolimus;Reactions Weekly;2020-10